Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger protein 138, E3 ubiquitin protein ligase pseudogene 2 (RNF138P2)
- Target
- RNF138P2
- Molecular classification
- Other (Pseudogene)
01
Overview
Ring finger protein 138 pseudogene 2 (RNF138P2) is a genomic DNA segment in humans that resembles the protein-coding gene Ring finger protein 138 (RNF138), which encodes an E3 ubiquitin ligase involved in DNA damage response and repair. RNF138P2 itself is classified as a pseudogene, meaning it does not produce a functional protein due to disabling mutations and/or missing regulatory sequences. While most pseudogenes were historically viewed as nonfunctional "junk DNA," some recent studies have indicated that transcribed pseudogenes may play regulatory roles through noncoding RNA pathways, such as modulating microRNA activity or generating short interfering RNAs. However, there is currently no published evidence that RNF138P2 is therapeutically actionable, functionally relevant in disease, or useful as a biomarker. The true drug target is RNF138, not this pseudogene variant.
- Other names
- Ring finger protein 138 pseudogene 2RNF138P2Ring finger protein 138, E3 ubiquitin protein ligase pseudogene 2
02
Mechanism of action
None directly attributable. Mechanisms relevant to pseudogenes may include competitive endogenous RNA (ceRNA) effects, but no specific mechanism is established for RNF138P2
03
Biological functions
Potential regulatory noncoding RNA (possible microRNA sponge or source for small interfering RNAs)No direct biological function as a protein, but pseudogenes may influence the expression of their parent genes or related genes via RNA-level mechanisms, for example acting as miRNA decoys or being processed into regulatory siRNAs
04
Disease associations
Other: Pseudogenes can be deregulated in cancer and may participate in noncoding regulatory networks, but RNF138P2 itself has not been specifically linked to a disease role in published studiesNo direct disease association for RNF138P2
05
Safety considerations
None described. There are no safety concerns or therapeutic challenges since there are no therapeutics acting on RNF138P2
06
Interacting drugs
None. There are no known drugs that directly target RNF138P2, since it does not encode a functional protein
07
Biomarkers
None. RNF138P2 is not described in the literature as a biomarker for patient selection or monitoring
Beyond the preview
Go deeper on Ring finger protein 138, E3 ubiquitin protein ligase pseudogene 2 (RNF138P2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ring finger protein 138, E3 ubiquitin protein ligase pseudogene 2 (RNF138P2).